Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Allergovit 6-Grasses in Grass Pollen Allergy
NCT00263601Phase 3Completed
- Sponsor
- Allergopharma
- Start
- Nov 2001
- Primary completion
- May 2004
- Modality
- Peptides, Peptide-based Cancer Vaccines, Allergy Immunotherapy
- Countries
- 1
01
Overview
A Phase 3 trial of Allergovit in allergic rhinoconjunctivitis (ARC), sponsored by Allergopharma. Started Nov 2001; status: completed.
02
Drugs
Allergovit
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00263601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263601.